01Purpose and principlesWhat the treatment does and how it fits into care.
Cytotoxic chemotherapy can be curative, neoadjuvant, adjuvant or palliative. Cell kill often relates to dose and schedule, but normal marrow, gastrointestinal mucosa, hair follicles and gonads are also affected. Combination regimens balance non-overlapping mechanisms, resistance and toxicity. The national or network protocol is the prescribing source because small differences in route, day, sequence and supportive care are clinically important.
Safe SACT delivery uses protocol matching, independent verification and prospective review before each cycle. Full blood count and organ function determine whether treatment proceeds, is delayed or modified. Previous toxicity, infection, performance status, body-weight change and interacting medicines matter as much as a threshold result. Central access, vesicant status and infusion-reaction precautions are checked before administration.
Toxicity continues after discharge. Patients need a thermometer where appropriate, immediate contact instructions and clarity that fever, shivering, breathlessness, diarrhoea or sudden illness must not wait for routine review. Acute oncology should receive regimen, cycle day, expected nadir and prophylaxis. After treatment, surveillance includes late cardiac, pulmonary, renal, neurological, fertility and second-malignancy effects according to exposure.
Key points
- Cytotoxic medicines damage dividing cells through DNA injury, antimetabolite action, mitotic disruption or topoisomerase effects; combinations attack different vulnerabilities but compound toxicity.
- Regimen choice depends on histology, stage, intent, biomarkers, prior therapy, organ function and patient goals; the protocol specifies medicines, sequence, cycle and modifications.
- Before every cycle verify identity, consent, intent, performance, blood count, renal and hepatic function, toxicity, infection and dose changes through an independent SACT process.
- Dosing may use body surface area, weight, renal function or exposure-based calculation; never reconstruct a regimen from memory or copy a previous cycle blindly.
- Myelosuppression, mucositis, nausea, diarrhoea, alopecia, infertility and fatigue are common, while individual agents add cardiac, renal, pulmonary, neurological or bladder toxicity.
- Supportive antiemetics, growth-factor prophylaxis, hydration and infection prevention are regimen-specific and should be prescribed with the anticancer medicines.
- Suspected neutropenic sepsis is an acute medical emergency: assess and culture without delaying the first empirical antibiotic, aiming to administer it within 1 hour of acute presentation; a normal temperature or pending blood count does not make deterioration safe.
- Provide a 24-hour treatment line, written warning symptoms, reproductive advice and a medication-interaction plan before the first dose.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Neutrophils, platelets and haemoglobin may fall at a regimen-specific time, requiring trends and clinical assessment before redosing.
Fever, shivering, hypotension, confusion or unexplained deterioration after treatment needs immediate emergency antibiotics and sepsis care.
Flushing, urticaria, wheeze, chest discomfort, hypotension or back pain during infusion requires stopping administration and emergency assessment.
Neuropathy, mucositis, diarrhoea, renal decline, hepatic injury or cardiopulmonary symptoms can require delay, reduction or discontinuation.
Pain, swelling, erythema, resistance or absent blood return during vesicant infusion requires immediate stop and agent-specific management.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Full blood count before each cycleFirst step - Why
- Confirm marrow recovery and detect anaemia or thrombocytopenia.
- Interpretation and limitations
- Apply the exact regimen threshold and trajectory; unexpected pancytopenia also prompts infection, bleeding, marrow or medicine review.
- 02
Renal and hepatic profile - Why
- Determine clearance, organ toxicity and dose eligibility.
- Interpretation and limitations
- Use current protocol calculations and relevant baseline value; small creatinine changes can materially alter exposure for selected agents.
- 03
Baseline agent-specific assessment - Why
- Measure vulnerable organ reserve before exposure.
- Interpretation and limitations
- Depending on regimen this may include echocardiography, lung function, hearing, neuropathy, viral screening, pregnancy or pharmacogenomic testing.
- 04
Cultures and lactate in suspected sepsis - Why
- Identify infection and physiological severity without delaying antibiotics.
- Interpretation and limitations
- Take blood cultures including central-line samples promptly, but give empirical intravenous antibiotics within the emergency pathway.
- 05
Toxicity grading and medication review - Why
- Convert patient symptoms and interactions into a cycle decision.
- Interpretation and limitations
- Grade does not replace judgement; cumulative and quality-of-life effects can be significant before a nominal severe category.
04Treatment approachPreparation, options, escalation and aftercare.
01AuthoriseVerify every treatment cycleFirst stepA patient attends for protocol-based cytotoxic treatment.+
- 1Confirm identity, diagnosis, intent, consent, regimen, cycle, body size or renal calculation, allergies and previous dose modifications.
- 2Review performance, infection, toxicity, full blood count, renal, hepatic and agent-specific results against the current protocol.
- 3Authorise, delay, reduce or stop with documented rationale and independent pharmacy and administration checks; prescribe supportive care concurrently.
02DeliverAdminister through the correct routeThe cycle is authorised and prepared.+
- 1Confirm medicine, dose, sequence, route, access patency, vesicant precautions and premedication immediately before administration.
- 2Observe for infusion reaction and extravasation, stopping the drug while maintaining access if either is suspected and following the agent-specific kit.
- 3Provide written cycle dates, expected nadir, supportive medicines, 24-hour contact and emergency symptoms before discharge.
03RescueTreat acute toxicityFever, deterioration, severe gastrointestinal loss, organ symptoms or infusion injury occurs.+
- 1Use ABCDE assessment, contact acute oncology, identify the regimen and cycle day, and obtain urgent blood count, organ profile, lactate and cultures as indicated.
- 2Give the first empirical neutropenic-sepsis antibiotic immediately and target administration within 1 hour of acute presentation, while resuscitating shock and treating anaphylaxis or other organ emergencies without awaiting oncology review.
- 3Record the event, reconcile causality and prophylaxis, and require specialist reassessment before any further cycle.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Capecitabine (oral cytotoxic example)
A licensed monotherapy schedule is 1,250 mg/m² orally twice daily on days 1–14 of a 21-day cycle, taken within 30 minutes after food; combination protocols commonly use different starting doses. Calculate each dose and apply protocol, renal and toxicity modifications rather than copying this example.Check dihydropyrimidine dehydrogenase status before treatment. Diarrhoea, mucositis, hand-foot syndrome, marrow suppression and cardiotoxicity require prompt holds; severe renal impairment is contraindicated and major interactions include coumarin anticoagulants.
Piperacillin/tazobactam for suspected neutropenic sepsis
Give the first adult dose 4.5 g intravenously immediately; the licensed febrile-neutropenia schedule is 4.5 g every 6 hours, then modify to local microbiology, allergy, prior resistance, cultures and renal function. Do not add an aminoglycoside or glycopeptide routinely without a patient-specific or local indication.Take cultures without delaying treatment, verify severe beta-lactam allergy, adjust for renal impairment, review sodium load and monitor blood count, kidney, liver and microbiology. Escalate shock and source control in parallel.
Filgrastim for protocol-defined neutropenia prophylaxis
A usual cytotoxic-chemotherapy dose is 5 micrograms/kg subcutaneously once daily, started at least 24 hours after chemotherapy and continued until the expected neutrophil nadir has passed and recovery is sustained; follow the regimen and product-specific duration.It does not treat sepsis or replace immediate antibiotics. Bone pain is common; monitor blood count and consider rare splenic rupture, acute respiratory distress, capillary leak, aortitis and sickle-cell complications.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Before each cycle trend blood count, renal and hepatic function, weight, performance status, infection and cumulative toxicity against protocol.
- During infusion observe access, vital signs and agent-specific reactions, documenting total dose and any interruption accurately.
- Between cycles use a 24-hour treatment line and capture emergency attendance, antimicrobials, diarrhoea, vomiting, mucositis, bleeding and adherence.
- Reassess radiological and clinical response at the planned decision point rather than continuing a tolerated but ineffective regimen automatically.
- After completion monitor exposure-specific late cardiac, pulmonary, renal, neurological, endocrine, fertility and second-cancer risks.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Protocol is the prescription
A familiar drug name is insufficient because sequence, route, infusion time, supportive care and organ rules differ between regimens.
Nadir is not reassurance
A patient can develop sepsis before the expected lowest count, and clinical deterioration demands action regardless of calendar day.
Cumulative toxicity matters
Neuropathy, cardiac exposure and marrow injury can worsen cycle by cycle even when each individual administration appears tolerated.
Supportive care is treatment
Antiemesis, hydration, prophylaxis and emergency education determine whether intended dose and quality of life can be maintained.
Intent changes trade-offs
A toxicity accepted for realistic cure may be inappropriate for minimal palliative benefit; consent must make intent explicit.
08Common pitfallsFrequent interpretation and management errors.
- 01
Copying the previous cycle without fresh review.
- 02
Waiting for neutrophil results before sepsis antibiotics.
- 03
Ignoring route, sequence or vesicant status.
- 04
Forgetting cumulative and late toxicity.
- 05
Prescribing cytotoxic treatment without supportive medicines.
- 06
Continuing ineffective treatment because toxicity is acceptable.